Kyverna Therapeutics Common Stock Price Prediction
| KYTX Stock | 9.76 0.75 7.14% |
Momentum 49
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.87) | EPS Estimate Current Year (3.71) | EPS Estimate Next Year (3.41) | Wall Street Target Price 29.6 | EPS Estimate Current Quarter (0.95) |
Using Kyverna Therapeutics hype-based prediction, you can estimate the value of Kyverna Therapeutics Common from the perspective of Kyverna Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Kyverna Therapeutics using Kyverna Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Kyverna using crowd psychology based on the activity and movement of Kyverna Therapeutics' stock price.
Kyverna Therapeutics Short Interest
An investor who is long Kyverna Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Kyverna Therapeutics and may potentially protect profits, hedge Kyverna Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 5.0326 | Short Percent 0.0862 | Short Ratio 1.33 | Shares Short Prior Month 3.5 M | 50 Day MA 8.2258 |
Kyverna Therapeutics Hype to Price Pattern
Investor biases related to Kyverna Therapeutics' public news can be used to forecast risks associated with an investment in Kyverna. The trend in average sentiment can be used to explain how an investor holding Kyverna can time the market purely based on public headlines and social activities around Kyverna Therapeutics Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Kyverna Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Kyverna Therapeutics.
Kyverna Therapeutics Implied Volatility | 1.88 |
Kyverna Therapeutics' implied volatility exposes the market's sentiment of Kyverna Therapeutics Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Kyverna Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Kyverna Therapeutics stock will not fluctuate a lot when Kyverna Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Kyverna Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Kyverna because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Kyverna Therapeutics after-hype prediction price | USD 9.44 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Kyverna contract
Based on the Rule 16, the options market is currently suggesting that Kyverna Therapeutics Common will have an average daily up or down price movement of about 0.12% per day over the life of the 2026-03-20 option contract. With Kyverna Therapeutics trading at USD 9.76, that is roughly USD 0.0115 . If you think that the market is fully incorporating Kyverna Therapeutics' daily price movement you should consider acquiring Kyverna Therapeutics Common options at the current volatility level of 1.88%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Kyverna Therapeutics Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kyverna Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kyverna Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Kyverna Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kyverna Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kyverna Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Kyverna Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Kyverna Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kyverna Therapeutics' historical news coverage. Kyverna Therapeutics' after-hype downside and upside margins for the prediction period are 1.59 and 17.29, respectively. We have considered Kyverna Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Kyverna Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Kyverna Therapeutics is based on 3 months time horizon.
Kyverna Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Kyverna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kyverna Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kyverna Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.68 | 7.85 | 0.32 | 0.11 | 9 Events / Month | 8 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
9.76 | 9.44 | 3.28 |
|
Kyverna Therapeutics Hype Timeline
Kyverna Therapeutics is now traded for 9.76. The entity has historical hype elasticity of -0.32, and average elasticity to hype of competition of 0.11. Kyverna is anticipated to decline in value after the next headline, with the price expected to drop to 9.44. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.28%, whereas the daily expected return is now at 0.68%. The volatility of related hype on Kyverna Therapeutics is about 4875.78%, with the expected price after the next announcement by competition of 9.87. About 54.0% of the company shares are owned by institutional investors. The book value of Kyverna Therapeutics was now reported as 3.47. The company recorded a loss per share of 3.73. Kyverna Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 9 days. Check out Kyverna Therapeutics Basic Forecasting Models to cross-verify your projections.Kyverna Therapeutics Related Hype Analysis
Having access to credible news sources related to Kyverna Therapeutics' direct competition is more important than ever and may enhance your ability to predict Kyverna Therapeutics' future price movements. Getting to know how Kyverna Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kyverna Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ALLO | Allogene Therapeutics | (0.01) | 12 per month | 3.24 | 0.1 | 9.76 | (5.93) | 21.23 | |
| LXEO | Lexeo Therapeutics Common | (0.25) | 7 per month | 0.00 | (0.05) | 7.04 | (8.50) | 34.26 | |
| CABA | Cabaletta Bio | (0.06) | 9 per month | 4.89 | 0.05 | 10.58 | (8.79) | 62.77 | |
| CTNM | Contineum Therapeutics Class | 0.07 | 8 per month | 4.11 | 0.06 | 7.89 | (5.55) | 23.16 | |
| EDIT | Editas Medicine | 0.23 | 9 per month | 0.00 | (0.21) | 6.56 | (9.13) | 18.33 | |
| MREO | Mereo BioPharma Group | 0.07 | 8 per month | 0.00 | (0.01) | 16.33 | (9.52) | 101.95 | |
| AVIR | Atea Pharmaceuticals | 0.02 | 10 per month | 2.89 | 0.11 | 4.64 | (3.27) | 16.12 | |
| CAPR | Capricor Therapeutics | 1.60 | 10 per month | 4.29 | 0.12 | 11.97 | (10.26) | 386.29 | |
| LYEL | Lyell Immunopharma | 0.24 | 9 per month | 4.09 | 0.10 | 12.12 | (7.92) | 31.14 | |
| SLN | Silence Therapeutics PLC | (0.30) | 8 per month | 0.00 | (0.09) | 6.88 | (5.28) | 22.91 |
Kyverna Therapeutics Additional Predictive Modules
Most predictive techniques to examine Kyverna price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kyverna using various technical indicators. When you analyze Kyverna charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Kyverna Therapeutics Predictive Indicators
The successful prediction of Kyverna Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kyverna Therapeutics Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kyverna Therapeutics based on analysis of Kyverna Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kyverna Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kyverna Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 3.05 | 8.61 | 7.75 | 4.19 | Net Debt To EBITDA | 0.44 | 0.71 | 0.81 | 1.33 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.